C1抑制剂治疗重度补体介导的自身免疫性溶血性贫血患者
这项前瞻性、单中心、2期、开放标签试验纳入10例确诊补体介导的自身免疫性溶血性贫血且需输注2单位红细胞的成人患者,在输血前后给予4剂静脉C1抑制剂(6000、3000、2000、1000 U,间隔12小时)。C1抑制剂使血浆C1抑制剂抗原和活性升高、红细胞C3d沉积显著减少,但溶血、炎症和补体活化标志物总体未变,血红蛋白短暂升高后48小时内回到基线,未能阻止溶血。
要点
- C1抑制剂可暂时降低补体活化并减少红细胞C3d沉积。
- 在重度输血依赖的补体介导AIHA中,C1抑制剂未能阻止溶血活性。
- 血红蛋白输血后短暂升高,但48小时内回到基线。
核心结论
- 围输血期C1抑制剂可暂时降低补体活化,但未能阻止重度输血依赖的补体介导自身免疫性溶血性贫血患者的溶血活性。
- 不能排除若无C1抑制剂,输血后溶血活性会更高。
- 补体抑制对重度补体介导自身免疫性溶血性贫血输血疗效的潜在作用仍有待确定。
研究设计与样本
- 前瞻性、单中心、2期、开放标签试验(EudraCT2012-003710-13)。
- 纳入确诊补体介导的自身免疫性溶血性贫血且有输注2单位红细胞指征的患者,共10例。
- 在红细胞输注前后给予4剂静脉C1抑制剂(6000、3000、2000、1000 U),间隔12小时。
- 系列采血检测溶血活性、红细胞调理、补体活化和炎症标志物。
主要发现
- C1抑制剂给药后血浆C1抑制剂抗原和活性升高,于首剂后48小时达峰,并伴红细胞C3d沉积显著减少。
- 血红蛋白在输血后短暂升高,但48小时内回到基线。
- 溶血、炎症和补体活化标志物总体保持不变。
- 发生5例3级和1例4级不良事件,均被认为与研究药物无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 不能排除若无C1抑制剂,输血后溶血活性会更高。
- 补体抑制对重度补体介导自身免疫性溶血性贫血输血疗效的潜在作用仍有待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Complement-mediated (CM) autoimmune hemolytic anemia (AIHA) is characterized by the destruction of red blood cells (RBCs) by autoantibodies that activate the classical complement pathway. These antibodies also reduce transfusion efficacy via the lysis of donor RBCs. Because C1-inhibitor (C1-INH) is an endogenous regulator of the classical complement pathway, we hypothesized that peritransfusional C1-INH in patients with severe CM-AIHA reduces complement activation and hemolysis, and thus enhances RBC transfusion efficacy. We conducted a prospective, single-center, phase 2, open-label trial (EudraCT2012-003710-13). Patients with confirmed CM-AIHA and indication for the transfusion of 2 RBC units were eligible for inclusion. Four IV C1-INH doses (6000, 3000, 2000, and 1000 U) were administered with 12-hour intervals around RBC transfusion. Serial blood samples were analyzed for hemolytic activity, RBC opsonization, complement activation, and inflammation markers. Ten patients were included in the study. C1-INH administration increased plasma C1-INH antigen and activity, peaking at 48 hours after the first dose and accompanied by a significant reduction of RBC C3d deposition. Hemoglobin levels increased briefly after transfusion but returned to baseline within 48 hours. Overall, markers of hemolysis, inflammation, and complement activation remained unchanged. Five grade 3 and 1 grade 4 adverse event occurred but were considered unrelated to the study medication. In conclusion, peritransfusional C1-INH temporarily reduced complement activation. However, C1-INH failed to halt hemolytic activity in severe transfusion-dependent-CM-AIHA. We cannot exclude that posttransfusional hemolytic activity would have been even higher without C1-INH. The potential of complement inhibition on transfusion efficacy in severe CM-AIHA remains to be determined.
引用
- de Boer ECW, Jalink M, Delvasto-Nuñez L, et al. C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia. Blood Adv. 2023. PMID: 36920779. doi:10.1182/bloodadvances.2022009402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。